Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

about

Autoimmunity in narcolepsy.

P2860

Q46172090-B96E0448-AE08-49C4-9C9D-2BC8B1014924

P2860

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

Item

http://www.wikidata.org/entity/Q41118592

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

@en

type

Item

label

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

@en

prefLabel

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

@en

P1476

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

@en

P2093

Quentin Canelle

http://www.w3.org/2001/XMLSchema#string

Robbert van der Most

http://www.w3.org/2001/XMLSchema#string

Walthère Dewé

http://www.w3.org/2001/XMLSchema#string

P2860

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.

Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.

Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data.

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development.

Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.

P304

2289-2298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2016.1168954

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bruce L. Innis

P577

2016-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27105343

http://www.w3.org/2001/XMLSchema#string

P932

5027709

http://www.w3.org/2001/XMLSchema#string

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

about

P2860

P2860

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932